CN103520829A - Ultrasound and static electricity compound transdermal delivery system - Google Patents
Ultrasound and static electricity compound transdermal delivery system Download PDFInfo
- Publication number
- CN103520829A CN103520829A CN201210580806.3A CN201210580806A CN103520829A CN 103520829 A CN103520829 A CN 103520829A CN 201210580806 A CN201210580806 A CN 201210580806A CN 103520829 A CN103520829 A CN 103520829A
- Authority
- CN
- China
- Prior art keywords
- delivery system
- sensitive adhesive
- layer
- drug delivery
- static
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to the technical field of medicine, in particular to a drug delivery system, and discloses an ultrasound and static electricity compound transdermal delivery system. The ultrasound and static electricity compound transdermal delivery system comprises an isolation layer and a medicine containing pressure-sensitive adhesive layer which is arranged on the inner side of the isolation layer. The ultrasound and static electricity compound transdermal delivery system is characterized in that an electret layer made of electret materials is arranged on the outer side of the isolation layer, and a controlled release film layer is arranged on the inner side of the medicine containing pressure-sensitive adhesive layer; the electret layer, the isolation layer, the medicine containing pressure-sensitive adhesive layer and the controlled release film layer are arranged in sequence from outside to inside to form a storage type patch; an ultrasound generation layer adheres to the outer side of the medicine containing pressure-sensitive adhesive layer, and is connected with an ultrasound generation circuit. When ultrasound given out by the ultrasound generation layer acts on the medicine containing pressure-sensitive adhesive layer, the activity of medicine can be improved, the activity of moisture in the skin can be improved, and absorption of the medicine can be promoted.
Description
Technical field
The present invention relates to medical technical field, be specifically related to a kind of drug-supplying system.
Background technology
Transdermal drug delivery system refers in skin surface administration, makes medicine with constant rate of speed or approach constant rate of speed by skin, to enter body and circulate, and produces the novel form of whole body or local therapeutic effects.Its advantage applies exists: drug absorption is not affected by the factors such as PH in digestive tract, food, transhipment time; Avoid liver to be subject to effect; Overcome because absorbing the too high untoward reaction causing of too fast generation haemoconcentration; Sustainable control injection speed, flexible administration etc.
But existing transdermal drug delivery system is normal, exist defects such as drug molecule amount and polarity limit to some extent, also have the problems such as drug delivery dosage is not easy to control, breathability is poor.
Also there is the shortcomings such as seepage velocity is slow, drug utilization is abundant not in existing transdermal drug delivery system in addition.
Summary of the invention
The object of the invention is to, a kind of ultrasonic compound transdermal drug delivery system of static that involves is provided, solve above technical problem.
Technical problem solved by the invention can realize by the following technical solutions:
The ultrasonic compound transdermal drug delivery system of static that involves, comprise a sealing coat, be arranged on the pastille pressure-sensitive adhesive layer of described sealing coat inner side, it is characterized in that, the outside of described sealing coat is provided with the electret layer that an employing electret is made, and the inner side of described pastille pressure-sensitive adhesive layer is provided with a controlled release rete;
By outer and interior described electret layer, described sealing coat, described pastille pressure-sensitive adhesive layer and the described controlled release rete of being placed with successively, form a reservoir devices patch;
A ultrasound wave genetic horizon is posted in described pastille pressure-sensitive adhesive layer outside, and ultrasound wave genetic horizon is connected with a ultrasonic output circuit.
The ul-trasonic irradiation that ultrasound wave genetic horizon sends, in described pastille pressure-sensitive adhesive layer, can improve pharmaceutically active, improve water activity promotion drug absorption in skin.
The acoustic pressure that ultrasound wave produces simultaneously can act on pastille pressure-sensitive adhesive layer and skin, by acoustic pressure, impels drug absorption.
Described ultrasound wave genetic horizon can be arranged between described sealing coat and described pastille pressure-sensitive adhesive layer, also can be arranged between described electret layer and described sealing coat, or also can be arranged on described electret layer outside.
Described ultrasound wave genetic horizon adopts a piezoceramics layer.So that simplified structure and be beneficial to skin.
The described ultrasonic compound transdermal drug delivery system of static that involves also comprises a flexible substrate, and described reservoir devices patch is arranged on described flexible substrate, and the area of described flexible substrate is greater than described reservoir devices patch area; Described ultrasonic output circuit is arranged on the described flexible substrate of described reservoir devices patch avris.
Flexible substrate adopts cloth, contains 10% ~ 50% apocynum fibre in described cloth.Apocynum fibre can send the far infrared light wave of 8 ~ 15 microns, 86% radiance, and far infrared light wave acts on the food such as vegetable and fruit, and both non-toxic reaction, can slow down again the vitamin oxidation of food, and the loss of moisture, plays fresh-keeping effect.The present invention who contains apocynum fibre, neither can affect the effect of sack itself, has again preservation.
In described cloth, contain copper ion.Described copper ion good anti-bacterial effect, antibacterial range are wide, and to article non-toxic reaction.The composite antibacterial ability of apocynum fibre and copper ion is stronger, and due to the effect of copper ion, makes described antibiotic layer be blue, and the present invention inner side that described bag body inner side is provided with antibiotic layer is also blue, uses elegant in appearance.
In containing in described cloth, also contain 5% ~ 30%AB anti-bacterial fibre, described AB anti-bacterial fibre has the effect of 15 kinds of antibacterials such as eliminating staphylococcus aureus, Staphylococcus albus, Candida albicans, bacillus subtilis, escherichia coli, gonococcus, halophilic bacteria, bacillus pyocyaneus, Bacillus typhi, group B streptococcus, bactericidal effect is good, safe and reliable.
Described ultrasonic output circuit is provided with a power interface, by described power interface, connects a power supply.The present invention does not preferably involve internal battery on the compound transdermal drug delivery system of static ultrasonic, to avoid, because battery fluid is revealed, causes environmental pollution.
A metal electrode layer is also posted in described electret layer outside.To improve performance.
In described pastille pressure-sensitive adhesive layer, be also distributed with permanent magnet powder granule.Permanent magnet powder granule can adopt Ru-Fe-Mn permanent magnet powder granule.By magnetic field, molecular activity can be promoted, the activity of hydrone in human body can be promoted especially.
In described pastille pressure-sensitive adhesive layer, be also distributed with tourmaline powder particle.
Tourmaline is called again tourmaline.Tourmaline powder particle is blended in described pastille pressure-sensitive adhesive layer, there is the blood circulation of human body of promotion, improve cytoactive, improve electret electric field, human body is carried out to the advantages such as mineral supplements.
Reservoir devices patch of the present invention can avoid peroral dosage form to stimulate gastrointestinal, has also overcome the use inconvenience of other short infiltration methods, to defects such as drug molecule amount and polarity limit to some extent; Can reduce whole body blood drug level, improve local affected part drug level simultaneously; Adjustment by administration area can be controlled dosage, and medicine is with Zero order controlled releasing, 24 hours sustained release medicines, thus make curative effect long lasting and stable; Only need throw off patch gets final product interruption of the administration, easy to use.Electret can standby storage space electric charge and dipole electric charge, and its chemical stability is good, moisture resistant performance is good, surface point position is high, charge stability good, driving force meets the specific (special) requirements of Transdermal absorption by force, completely.The present invention adopts electret as the physical regulating factor, can be used as ion-drive source and provides electrostatic field and micro-electric current to skin, the electret state of regulation and control skin, electric structure and enhancing ionic drug Transdermal absorption.
Drug-supplying system of the present invention possesses that preparation method is simple, transdermal effect good, dose composition is controlled and the six large features such as slow release, good permeability,, convenient operation non-stimulated to skin.
Described electret layer can adopt the electret layer of non-porous formula.Can adopt the electret layer of porous type.
In described pastille pressure-sensitive adhesive layer, be also provided with viscosifier, transdermal enhancer and the antioxidant being dispersed in described substrate.So that better collaborative urging oozed together.
Accompanying drawing explanation
Fig. 1 is part-structure schematic diagram of the present invention.
The specific embodiment
For technological means, creation characteristic that the present invention is realized, reach object and effect is easy to understand, below in conjunction with concrete diagram, further set forth the present invention.
With reference to Fig. 1, the ultrasonic compound transdermal drug delivery system of static that involves, comprises a sealing coat 2, is arranged on the pastille pressure-sensitive adhesive layer 4 of sealing coat 2 inner sides, the outside of sealing coat 2 is provided with the electret layer 1 that an employing electret is made, and the inner side of pastille pressure-sensitive adhesive layer 4 is provided with a controlled release rete 5.By outer and interior electret layer 1, sealing coat 2, pastille pressure-sensitive adhesive layer 4 and the controlled release rete 5 of being placed with successively, form a reservoir devices patch.A ultrasound wave genetic horizon is posted in pastille pressure-sensitive adhesive layer 4 outsides, and ultrasound wave genetic horizon is connected with a ultrasonic output circuit.
The ul-trasonic irradiation that ultrasound wave genetic horizon sends, in pastille pressure-sensitive adhesive layer 4, can improve pharmaceutically active, improve water activity promotion drug absorption in skin.The acoustic pressure that ultrasound wave produces simultaneously can act on pastille pressure-sensitive adhesive layer 4 and skin, by acoustic pressure, impels drug absorption.
Ultrasound wave genetic horizon can be arranged between sealing coat 2 and pastille pressure-sensitive adhesive layer 4, also can be arranged between electret layer 1 and sealing coat 2, or also can be arranged on electret layer 1 outside.Ultrasound wave genetic horizon adopts a piezoceramics layer 3.So that simplified structure and be beneficial to skin.
The ultrasonic compound transdermal drug delivery system of static that involves also comprises a flexible substrate, and reservoir devices patch is arranged on flexible substrate, and the area of flexible substrate is greater than reservoir devices patch area.Ultrasonic output circuit is arranged on the flexible substrate of reservoir devices patch avris.
Flexible substrate adopts cloth, contains 10% ~ 50% apocynum fibre in cloth.Apocynum fibre can send the far infrared light wave of 8 ~ 15 microns, 86% radiance, and far infrared light wave acts on the food such as vegetable and fruit, and both non-toxic reaction, can slow down again the vitamin oxidation of food, and the loss of moisture, plays fresh-keeping effect.The present invention who contains apocynum fibre, neither can affect the effect of sack itself, has again preservation.
In cloth, contain copper ion.Copper ion good anti-bacterial effect, antibacterial range are wide, and to article non-toxic reaction.The composite antibacterial ability of apocynum fibre and copper ion is stronger, and due to the effect of copper ion, makes antibiotic layer be blue, and the present invention inner side that bag body inner side is provided with antibiotic layer is also blue, uses elegant in appearance.
In containing in cloth, also contain 5% ~ 30%AB anti-bacterial fibre, AB anti-bacterial fibre has the effect of 15 kinds of antibacterials such as eliminating staphylococcus aureus, Staphylococcus albus, Candida albicans, bacillus subtilis, escherichia coli, gonococcus, halophilic bacteria, bacillus pyocyaneus, Bacillus typhi, group B streptococcus, bactericidal effect is good, safe and reliable.
Ultrasonic output circuit is provided with a power interface, by power interface, connects a power supply.The present invention does not preferably involve internal battery on the compound transdermal drug delivery system of static ultrasonic, to avoid, because battery fluid is revealed, causes environmental pollution.A metal electrode layer is also posted in electret layer 1 outside.To improve performance.
In pastille pressure-sensitive adhesive layer 4, be also distributed with permanent magnet powder granule 6.Permanent magnet powder granule 6 can adopt Ru-Fe-Mn permanent magnet powder granule 6.By magnetic field, molecular activity can be promoted, the activity of hydrone in human body can be promoted especially.In pastille pressure-sensitive adhesive layer 4, be also distributed with tourmaline powder particle.
Tourmaline is called again tourmaline.Tourmaline powder particle is blended in pastille pressure-sensitive adhesive layer 4, there is the blood circulation of human body of promotion, improve cytoactive, improve electret electric field, human body is carried out to the advantages such as mineral supplements.
Reservoir devices patch of the present invention can avoid peroral dosage form to stimulate gastrointestinal, has also overcome the use inconvenience of other short infiltration methods, to defects such as drug molecule amount and polarity limit to some extent; Can reduce whole body blood drug level, improve local affected part drug level simultaneously; Adjustment by administration area can be controlled dosage, and medicine is with Zero order controlled releasing, 24 hours sustained release medicines, thus make curative effect long lasting and stable; Only need throw off patch gets final product interruption of the administration, easy to use.Electret can standby storage space electric charge and dipole electric charge, and its chemical stability is good, moisture resistant performance is good, surface point position is high, charge stability good, driving force meets the specific (special) requirements of Transdermal absorption by force, completely.The present invention adopts electret as the physical regulating factor, can be used as ion-drive source and provides electrostatic field and micro-electric current to skin, the electret state of regulation and control skin, electric structure and enhancing ionic drug Transdermal absorption.
Drug-supplying system of the present invention possesses that preparation method is simple, transdermal effect good, dose composition is controlled and the six large features such as slow release, good permeability,, convenient operation non-stimulated to skin.Electret layer 1 can adopt the electret layer 1 of non-porous formula.Can adopt the electret layer 1 of porous type.
In pastille pressure-sensitive adhesive layer 4, be also provided with the viscosifier, transdermal enhancer and the antioxidant that are dispersed in substrate.So that better collaborative urging oozed together.
More than show and described ultimate principle of the present invention and principal character and advantage of the present invention.The technical staff of the industry should understand; the present invention is not restricted to the described embodiments; that in above-described embodiment and description, describes just illustrates principle of the present invention; without departing from the spirit and scope of the present invention; the present invention also has various changes and modifications, and these changes and improvements all fall in the claimed scope of the invention.The claimed scope of the present invention is defined by appending claims and equivalent thereof.
Claims (10)
1. the ultrasonic compound transdermal drug delivery system of static that involves, comprise a sealing coat, be arranged on the pastille pressure-sensitive adhesive layer of described sealing coat inner side, it is characterized in that, the outside of described sealing coat is provided with the electret layer that an employing electret is made, and the inner side of described pastille pressure-sensitive adhesive layer is provided with a controlled release rete;
By outer and interior described electret layer, described sealing coat, described pastille pressure-sensitive adhesive layer and the described controlled release rete of being placed with successively, form a reservoir devices patch;
A ultrasound wave genetic horizon is posted in described pastille pressure-sensitive adhesive layer outside, and ultrasound wave genetic horizon is connected with a ultrasonic output circuit.
2. the ultrasonic compound transdermal drug delivery system of static that involves according to claim 1, is characterized in that, described ultrasound wave genetic horizon adopts a piezoceramics layer.
3. the ultrasonic compound transdermal drug delivery system of static that involves according to claim 2, is characterized in that, described ultrasound wave genetic horizon is arranged between described sealing coat and described pastille pressure-sensitive adhesive layer.
4. the ultrasonic compound transdermal drug delivery system of static that involves according to claim 2, is characterized in that, described ultrasound wave genetic horizon is arranged between described electret layer and described sealing coat.
5. the ultrasonic compound transdermal drug delivery system of static that involves according to claim 2, is characterized in that, described ultrasound wave genetic horizon is arranged on described electret layer outside.
6. according to the ultrasonic compound transdermal drug delivery system of static that involves described in claim 1,2,3,4 or 5, it is characterized in that, a metal electrode layer is also posted in described electret layer outside.
7. the ultrasonic compound transdermal drug delivery system of static that involves according to claim 6, is characterized in that, in described pastille pressure-sensitive adhesive layer, is also distributed with permanent magnet powder granule, and permanent magnet powder granule adopts Ru-Fe-Mn permanent magnet powder granule.
8. the ultrasonic compound transdermal drug delivery system of static that involves according to claim 7, it is characterized in that, the described ultrasonic compound transdermal drug delivery system of static that involves also comprises a flexible substrate, described reservoir devices patch is arranged on described flexible substrate, and the area of described flexible substrate is greater than described reservoir devices patch area; Described ultrasonic output circuit is arranged on the described flexible substrate of described reservoir devices patch avris.
9. the ultrasonic compound transdermal drug delivery system of static that involves according to claim 7, is characterized in that, in described pastille pressure-sensitive adhesive layer, is also distributed with tourmaline powder particle.
10. the ultrasonic compound transdermal drug delivery system of static that involves according to claim 8, is characterized in that, described flexible substrate adopts cloth, contains 10% ~ 50% apocynum fibre in cloth; In cloth, contain copper ion; In also containing in cloth, also contain 5% ~ 30%AB anti-bacterial fibre.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210580806.3A CN103520829B (en) | 2012-12-27 | 2012-12-27 | Ultrasonicly involve static electricity compound transdermal delivery system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210580806.3A CN103520829B (en) | 2012-12-27 | 2012-12-27 | Ultrasonicly involve static electricity compound transdermal delivery system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103520829A true CN103520829A (en) | 2014-01-22 |
| CN103520829B CN103520829B (en) | 2016-03-02 |
Family
ID=49923408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210580806.3A Active CN103520829B (en) | 2012-12-27 | 2012-12-27 | Ultrasonicly involve static electricity compound transdermal delivery system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103520829B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816443A (en) * | 2016-01-05 | 2016-08-03 | 中国人民解放军第二军医大学 | GLP-1 sustained-release electret transdermal drug delivery system for treating diabetes |
| CN105816442A (en) * | 2016-01-05 | 2016-08-03 | 中国人民解放军第二军医大学 | 5-fluorouracil nanoparticle transdermal drug delivery electret preparation for treating hypertrophic scars based on action of electric field |
| CN106074460A (en) * | 2016-07-12 | 2016-11-09 | 中国人民解放军第二军医大学 | A kind of electret and the Percutaneously administrable preparation of 5 fluorouracil associating Inhibiting proliferation cicatrix growth |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4734090A (en) * | 1986-07-18 | 1988-03-29 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator |
| WO2007122226A2 (en) * | 2006-04-26 | 2007-11-01 | Dbv Technologies | Patch and uses thereof |
| CN101090012A (en) * | 2007-04-27 | 2007-12-19 | 新康电脑科技（苏州）有限公司 | Far infrared/strong magnetic fied function material |
| CN101143242A (en) * | 2007-11-13 | 2008-03-19 | 重庆市生力医疗设备有限公司 | Ultrasonic medicine plaster |
| CN101460214A (en) * | 2006-06-24 | 2009-06-17 | Lts勒曼治疗系统股份公司 | Transdermal therapeutic system reinforced by ultrasounds |
| CN102015025A (en) * | 2008-02-15 | 2011-04-13 | 压电共振概念有限公司 | Transdermal micro-patch |
| CN202314980U (en) * | 2011-11-02 | 2012-07-11 | 四川康贝斯消毒药剂有限公司 | Heat release static physiotherapy patch |
| CN202397971U (en) * | 2011-11-18 | 2012-08-29 | 中国人民解放军第二军医大学 | Electret and microneedle transdermal delivery system |
-
2012
- 2012-12-27 CN CN201210580806.3A patent/CN103520829B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4734090A (en) * | 1986-07-18 | 1988-03-29 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator |
| WO2007122226A2 (en) * | 2006-04-26 | 2007-11-01 | Dbv Technologies | Patch and uses thereof |
| CN101460214A (en) * | 2006-06-24 | 2009-06-17 | Lts勒曼治疗系统股份公司 | Transdermal therapeutic system reinforced by ultrasounds |
| CN101090012A (en) * | 2007-04-27 | 2007-12-19 | 新康电脑科技（苏州）有限公司 | Far infrared/strong magnetic fied function material |
| CN101143242A (en) * | 2007-11-13 | 2008-03-19 | 重庆市生力医疗设备有限公司 | Ultrasonic medicine plaster |
| CN102015025A (en) * | 2008-02-15 | 2011-04-13 | 压电共振概念有限公司 | Transdermal micro-patch |
| CN202314980U (en) * | 2011-11-02 | 2012-07-11 | 四川康贝斯消毒药剂有限公司 | Heat release static physiotherapy patch |
| CN202397971U (en) * | 2011-11-18 | 2012-08-29 | 中国人民解放军第二军医大学 | Electret and microneedle transdermal delivery system |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816443A (en) * | 2016-01-05 | 2016-08-03 | 中国人民解放军第二军医大学 | GLP-1 sustained-release electret transdermal drug delivery system for treating diabetes |
| CN105816442A (en) * | 2016-01-05 | 2016-08-03 | 中国人民解放军第二军医大学 | 5-fluorouracil nanoparticle transdermal drug delivery electret preparation for treating hypertrophic scars based on action of electric field |
| CN106074460A (en) * | 2016-07-12 | 2016-11-09 | 中国人民解放军第二军医大学 | A kind of electret and the Percutaneously administrable preparation of 5 fluorouracil associating Inhibiting proliferation cicatrix growth |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103520829B (en) | 2016-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103285028B (en) | Composite antibacterial agent of chitosan and organosilicone quaternary ammonium salt and preparation method of composite antibacterial agent | |
| Zhou et al. | Rational design of intelligent and multifunctional dressing to promote acute/chronic wound healing | |
| CN102499944B (en) | Nanometer silver antibiotic and antiviral compound liquid and its preparation method and products | |
| CN103520829B (en) | Ultrasonicly involve static electricity compound transdermal delivery system | |
| CN109566954B (en) | Laurus essential oil and nano-silver embedded liposome/chitosan antibacterial and antioxidant coating solution and preparation method and application thereof | |
| CN105816952A (en) | Novel electret microneedle transdermal drug delivery system | |
| CN202397971U (en) | Electret and microneedle transdermal delivery system | |
| CN104399067A (en) | Veterinary preparation namely lysozyme-loaded chitosan microspheres and preparation method thereof | |
| CN103505806B (en) | electret nanoparticle transdermal drug delivery system | |
| CN103041400B (en) | Preparation method of antimicrobial peptide loaded chitosan/gamma polyglutamic acid composite nanoparticles | |
| Gangwar et al. | Recent advances in mupirocin delivery strategies for the treatment of bacterial skin and soft tissue infection | |
| CN105816442A (en) | 5-fluorouracil nanoparticle transdermal drug delivery electret preparation for treating hypertrophic scars based on action of electric field | |
| Jia et al. | Antibacterial Chemodynamic Therapy: Materials and Strategies | |
| CN202961235U (en) | Electret sustained-release transdermal drug delivery system | |
| CN103993060A (en) | Preparation method for controllable silk fibroin particle | |
| Zhao et al. | Recent Progress of Photothermal Therapy Based on Conjugated Nanomaterials in Combating Microbial Infections | |
| CN108653197B (en) | Carboxymethyl chitosan quaternary ammonium salt temperature-sensitive gel and preparation method thereof | |
| CN100333789C (en) | Gel gent of Chiense forest frog bactericidal peptide | |
| CN104740599A (en) | Compound housefly antimicrobial peptide preparation | |
| CN102058232A (en) | Cosmetic bottle with corrosion preventing cap | |
| CN104337797B (en) | A kind of preparation method of the composite drug-loaded tunica fibrosa of multiple medicine integrated-type | |
| CN106074460A (en) | A kind of electret and the Percutaneously administrable preparation of 5 fluorouracil associating Inhibiting proliferation cicatrix growth | |
| Sinha et al. | ROLE OF GREEN SILVER NANOPARTICLES IN SUPPRESSING VARIOUS HUMAN PATHOGENESIS. | |
| JP2013501775A5 (en) | ||
| CN201861045U (en) | Cosmetic bottle with anti-corrosion cover |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |